Efficacy

The POLARIX trial demonstrates POLIVY-R-CHP’s superiority over R-CHOP, now supported by extended follow-up data1,2,*

Watch experts perspectives

Specialist views covering a range of POLARIX trial topics

Dr Hervé Tilly

University of Rouen, France

Prof. Christopher Flowers

MD, Anderson Cancer Center, University of Texas

Dr Franck Morschhauser

MD, PhD Professor of Hematology,
University of Lille

Dr Laurie H. Sehn

MD, MPH Clinical Assistant
Professor with the BC Cancer Agency and University
of British Columbia

POLIVY-R-CHP brings clinically meaningful improvement over R-CHOP1

POLIVY-R-CHP was superior vs R-CHOP: there was a 27% reduction of the risk of progression, relapse or death compared to R-CHOP1

Stratified hazard ratio 0.73; 95% CI, 0.57–0.95; p=0.021

At 24 months, there was a 6.5% improvement in progression-free survival with POLIVY-R-CHP vs R-CHOP1

 

76.7% (95% CI, 72.7– 80.8) vs. 70.2% (95% CI, 65.8-74.6)1

PATIENT POPULATION


Long-term analysis reveals a continued benefit of POLIVY-R-CHP in PFS and an emerging trend in OS2


The extended 5-year analysis of POLARIX demonstrates the durable significant PFS benefit of POLIVY-R-CHP over R-CHOP1,2,3
 

Primary endpoint: Investigator-assessed Progression-free survival (PFS)

 

Investigator-assessed event-free survival (EFS†) – a key secondary endpoint – confirmed the PFS results and hence the clinical benefit demonstrated by POLIVY-R-CHP (HR = 0.75 [95% CI: 0.58, 0.96], p-value = 0.02).1 EFS showed a 25% reduction in the risk of death, progression, relapse, or other events.1,‡

Positive overall survival trend2

POLIVY-R-CHP was associated with numerically fewer deaths compared to R-CHOP after 5-year follow-up2
 

Overall survival (OS)

 
 
The 3-year overall survival analysis demonstrated an HR of 0.94 (95% CI, 0.67–1.33), which improved to 0.85 (95% CI, 0.63–1.15) at 5 years. Further follow-up will provide additional insights into these outcomes.1,2

“Out of every four patients that would potentially relapse on R-CHOP you’re now preventing one of those four patients from relapsing with the POLIVY-R-CHP combination.”

– Dr Laurie H. Sehn, MD, MPH

Clinical Assistant Professor with the BC Cancer Agency and University of British Columbia

 

Cumulative death incidence2


In a competing risk analysis for lymphoma-related versus non-lymphoma-related deaths, the cumulative incidence of lymphoma-related deaths at Year 5 was lower with POLIVY-R-CHP compared to R-CHOP2
 

Five-year probability of lymphoma- and non-lymphoma-related deaths (Expanded population)§

“What we want to do is try and cure them with front-line therapy, and we know that the stakes become a lot higher once they do relapse.”

– Dr Laurie H. Sehn

Clinical Assistant Professor with the BC Cancer Agency and University of British Columbia


 

POLIVY-R-CHP has the potential to decrease the burden of R/R disease1,2


Patients on POLIVY-R-CHP required 23% fewer subsequent lymphoma-related therapies compared to those on R-CHOP over 5 years2
 


Patients on POLIVY-R-CHP required 23% fewer subsequent lymphoma-related therapies compared to those on R-CHOP over 5 years2
 

Patients Receiving Subsequent Lymphoma Therapy throughout 5 years (ITT Population)

  • Fewer patients with POLIVY-R-CHP had subsequent lines of therapies (25.5% with POLIVY-R-CHP compared to 35.3% with R-CHOP)2
  • Among those patients, fewer needed intensive high-cost and high-risk therapies such as CAR-T and SCT2

Patient Population

What type of patients can benefit from POLIVY?

read more

*Stratified hazard ratios for 2 and 5 years were 0.73 (95% CI, 0.57–0.95; p=0.02) and 0.77 (95% CI, 0.62–0.97; p=0.02), respectively.1,2

†EFS defined as the time from randomization to the earliest occurrence of disease progression/relapse, death due to any cause, initiation of any non-protocol specified anti-lymphoma treatment, or biopsy-confirmed residual disease after treatment completion.1

‡Events of progression or relapse were assessed by the investigator. Other events are subsequent therapy for lymphoma or biopsy-confirmed residual disease after treatment.1

§Expanded population includes the addition of a China extension cohort (n=121); distribution of patient characteristics was not modified2

 

1L=first line; CAR-T=chimeric antigen receptor T-cell therapy; CCOD=clinical cut-off date; DLBCL=diffuse large B-cell lymphoma; HR=hazard ratio; NE=not able to be evaluated;
OS=overall survival; PFS=progression-free survival; POLIVY-R-CHP=polatuzumab vedotin + cyclophosphamide, doxorubicin, prednisone; R/R=relapsed or refractory; R-CHOP=rituximab + cyclophosphamide, doxorubicin, vincristine, prednisone; SCT=stem-cell therapy.

 

References:

  1. Tilly H, et al. N Engl J Med. 2022;386:351-63.
  2. Salles G, et al. Oral presentation at: 66th ASH; December 2024; San Diego, USA.
  3. Herrera A, et al. Poster presented at: 64th ASH; December 2022; New Orleans, USA.